New hope for Tough-to-Treat breast cancer in early trial

NCT ID NCT03616587

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This is a first-in-human study to find a safe dose of a new drug called AZD9833 for women with advanced breast cancer that has stopped responding to standard hormone therapies. The study will test AZD9833 alone and in combination with several other cancer drugs. The main goal is to check the safety and side effects of these treatments in about 400 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Aurora, Colorado, 80045, United States
Research Site

Sarasota, Florida, 34232, United States
Research Site

Philadelphia, Pennsylvania, 19111, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Salt Lake City, Utah, 84112, United States
Research Site

Barcelona, 08035, Spain
Research Site

Barcelona, 8036, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28050, Spain
Research Site

Seville, 41013, Spain
Research Site

Valencia, 46010, Spain
Research Site

Cambridge, CB2 0QQ, United Kingdom
Research Site

Leeds, LS9 7TF, United Kingdom
Research Site

London, SW2 6JJ, United Kingdom
Research Site

Manchester, M20 4GJ, United Kingdom
Research Site

Sutton, SM1 2DL, United Kingdom
Research Site

Sutton, SM2 5PT, United Kingdom

Conditions

Explore the condition pages connected to this study.

ER+ HER2- ADVANCED BREAST CANCER